溴隐亭治疗与围产期心肌病结局:EORP PPCM注册研究
基于EORP PPCM注册中552例围产期心肌病患者,85例(15%)在标准心衰治疗基础上接受溴隐亭治疗。完全病例分析显示溴隐亭与不良母体结局降低相关(OR 0.29,95%CI 0.10-0.83),经多重插补和逆概率加权校正后仍显著(OR 0.47,95%CI 0.31-0.70)。血栓栓塞事件两组差异无统计学意义。
要点
- 溴隐亭联合标准治疗与6个月母体结局改善相关。
- 完全病例分析OR 0.29,加权插补模型OR 0.47,均支持获益。
核心结论
- 在围产期心肌病女性中,标准治疗基础上加用溴隐亭与6个月后更好的母体结局相关。
研究设计与样本
- EORP PPCM注册研究的事后探索性非随机分析,纳入552例有随访数据的围产期心肌病患者。
- 主要暴露为溴隐亭治疗,主要终点为6个月内死亡或再入院或6个月时LVEF<35%的复合终点。
- 采用逆概率加权减少适应证混杂,多重插补处理缺失数据。
主要发现
- 552例中85例(15%)接受溴隐亭治疗;491例(89%)有主要终点数据。
- 多重插补及逆概率加权模型显示关联持续(OR 0.47,95%CI 0.31-0.70,P<0.001)。
临床怎么用
- 在围产期心肌病患者中,可考虑在标准心衰治疗基础上加用溴隐亭以改善6个月母体结局。
- 使用溴隐亭时需关注血栓栓塞风险,但本研究中两组血栓栓塞事件发生率未见显著差异。
局限性
- 本研究为探索性非随机分析,存在适应证混杂可能,尽管采用了逆概率加权等方法校正。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Peripartum cardiomyopathy (PPCM) remains a serious threat to maternal health around the world. While bromocriptine, in addition to standard treatment for heart failure, presents a promising pathophysiology-based disease-specific treatment option in PPCM, the evidence regarding its efficacy remains limited. This study aimed to determine whether bromocriptine treatment is associated with improved maternal outcomes in PPCM. METHODS: Peripartum cardiomyopathy patients from the EORP PPCM registry with available follow-up were included. The main exposure of this exploratory non-randomized analysis was bromocriptine treatment, and the main outcome was a composite endpoint of maternal outcome [death or hospital readmission within the first 6 months after diagnosis, or persistent severe left ventricular dysfunction (left ventricular ejection fraction < 35%) at 6-month follow-up]. Inverse probability weighting was used to minimize the effects of confounding by indication. Multiple imputation was used to account for the missing data. RESULTS: Among the 552 patients with PPCM, 85 were treated with bromocriptine (15%). The primary endpoint was available in 491 patients (89%) and occurred in 18 out of 82 patients treated with bromocriptine in addition to standard of care (22%) and in 136 out of 409 patients treated with standard of care (33%) (P = .044). In complete case analysis, bromocriptine treatment was associated with reduced adverse maternal outcome [odds ratio (OR) 0.29, 95% confidence interval (CI) 0.10-0.83, P = .021]. This association remained after applying multiple imputation and methods to correct for confounding by indication (inverse probability weighted model on imputed data: OR 0.47, 95% CI 0.31-0.70, P < 0.001). Thromboembolic events were observed in 6.0% of the patients in the bromocriptine group vs. 5.6% in the standard of care group (P = .900). CONCLUSIONS: Among women with PPCM, bromocriptine treatment in addition to standard of care was associated with better maternal outcomes after 6 months.
引用
- van der Meer P, van Essen BJ, Viljoen C, et al. Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry. Eur Heart J. 2025. PMID: 39221911. doi:10.1093/eurheartj/ehae559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。